Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies.
[BACKGROUND] Staging laparoscopy (SL) is performed to detect occult metastases in patients with localized pancreatic cancer.
- p-value P < 0.050
- 연구 설계 cross-sectional
APA
Stoop TF, Lutchman KRD, et al. (2026). Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies.. HPB : the official journal of the International Hepato Pancreato Biliary Association, 28(3), 313-323. https://doi.org/10.1016/j.hpb.2025.12.001
MLA
Stoop TF, et al.. "Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies.." HPB : the official journal of the International Hepato Pancreato Biliary Association, vol. 28, no. 3, 2026, pp. 313-323.
PMID
41421934
Abstract
[BACKGROUND] Staging laparoscopy (SL) is performed to detect occult metastases in patients with localized pancreatic cancer. However, current guideline recommendations vary widely on routinely performing SL. This global survey investigated use and indications of SL.
[METHODS] An online survey was sent to members of nine international societies and working groups. Information was obtained about SL use, indications SL and adjunct diagnostic modalities across four clinical scenarios.
[RESULTS] Among 617 responding surgeons (76 countries, six continents), 82% used SL which varied between regions (Americas 90%, Asia 85%, Oceania 81%, Europe 76%, Africa 59%; P < 0.050). Most perform SL during the same session as the scheduled laparotomy (63-79%). A SL was mainly performed at the time of upfront surgery (71%), after (60%) or before (37%) neoadjuvant/induction therapy, and before radiotherapy (31%). SL was mainly performed in selected patients, either based on indeterminate/suspicious lesions on cross-sectional imaging (78-87%), resectability status (54-64%), and/or elevated CA19-9 level (60-69%). Most common used adjuncts were cytological lavage (37-55%) and intra-abdominal liver ultrasonography (36-50%).
[CONCLUSION] Despite considerable global variability, SL is widely used to detect occult metastases in pancreatic cancer, mainly in high-risk patients and often during the scheduled laparotomy. The observed variability highlights the need for more evidence leading to stronger guideline recommendations.
[METHODS] An online survey was sent to members of nine international societies and working groups. Information was obtained about SL use, indications SL and adjunct diagnostic modalities across four clinical scenarios.
[RESULTS] Among 617 responding surgeons (76 countries, six continents), 82% used SL which varied between regions (Americas 90%, Asia 85%, Oceania 81%, Europe 76%, Africa 59%; P < 0.050). Most perform SL during the same session as the scheduled laparotomy (63-79%). A SL was mainly performed at the time of upfront surgery (71%), after (60%) or before (37%) neoadjuvant/induction therapy, and before radiotherapy (31%). SL was mainly performed in selected patients, either based on indeterminate/suspicious lesions on cross-sectional imaging (78-87%), resectability status (54-64%), and/or elevated CA19-9 level (60-69%). Most common used adjuncts were cytological lavage (37-55%) and intra-abdominal liver ultrasonography (36-50%).
[CONCLUSION] Despite considerable global variability, SL is widely used to detect occult metastases in pancreatic cancer, mainly in high-risk patients and often during the scheduled laparotomy. The observed variability highlights the need for more evidence leading to stronger guideline recommendations.
MeSH Terms
Humans; Pancreatic Neoplasms; Laparoscopy; Neoplasm Staging; Practice Patterns, Physicians'; Health Care Surveys; Predictive Value of Tests
같은 제1저자의 인용 많은 논문 (5)
- Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'.
- Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on Surgical and Oncological Outcome.
- Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX.
- Pancreatic cancer.
- Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study.